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Background: With a US Food and Drug Administration-labeled indication to treat 
  attention-deficit/hyperactivity disorder (ADHD), the nonstimulant guanfacine has become the 
preferred α2-agonist for ADHD treatment. However, significant interindividual variability has 
been observed in response to guanfacine. Consequently, hypotheses of a contributing interac-
tion with the ubiquitously expressed drug transporter, P-glycoprotein (P-gp), have arisen. We 
performed an in vitro study to determine if guanfacine is indeed a substrate of P-gp.
Methods: Intracellular accumulation of guanfacine was compared between P-gp expressing 
LLC-PK1/MDR1 cells and P-gp-negative LLC-PK1 cells to evaluate the potential interac-
tion between P-gp and guanfacine. Cellular retention of guanfacine was analyzed using a 
high-performance liquid chromatographic-ultraviolet method. Rhodamine6G, a known P-gp 
substrate, was included in the study as a positive control.
Results: At guanfacine concentrations of 50 µM and 5 µM, intracellular accumulation of 
guanfacine in LLC-PK1/MDR1 cells was, 35.9% ± 4.8% and 49.0% ± 28.3% respectively, of 
that in LLC-PK1 cells. In comparison, the concentration of rhodamine6G, the positive P-gp 
substrate, in LLC-PK1/MDR1 cells was only 5% of that in LLC-PK1 cells.
Conclusion: The results of the intracellular accumulation study suggest that guanfacine is, at 
best, a weak P-gp substrate. Therefore, it is unlikely that P-gp, or any genetic variants thereof, 
are a determining factor in the interindividual variability of response observed with guanfacine 
therapy.
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Introduction
Guanfacine, initially marketed as an antihypertensive agent, is a selective 
α2-adrenergic agonist believed to exert its antihypertensive activity by decreasing 
sympathetic tone in the central nervous system and reducing vascular resistance.1 
However, because of its preferential effects on α2A-adrenoreceptors, which are 
believed to play a role in attentional and organizational functions in the prefron-
tal cortex, guanfacine became a drug of interest in the treatment of attention-
deficit/hyperactivity disorder (ADHD).2,3 Although psychostimulants, such 
as methylphenidate and amphetamine, are considered first-line treatments for 
ADHD, they are discontinued in approximately 5% of patients due to lack of 
efficacy or unwanted side effects.4 When psychostimulants are   ineffective or 
only partially effective in reducing target symptoms, clinicians may opt to utilize 
nonstimulant medications, such as the α2-agonists clonidine and guanfacine, as 
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the α2A-adrenoreceptor, a longer half-life, a potentially 
decreased side effect burden, and a US Food and Drug 
Administration-labeled indication to treat ADHD as 
monotherapy or as an adjunct to stimulant medications, 
guanfacine has become the preferred α2-agonist for use in 
ADHD.5 Additionally, a number of published   studies have 
demonstrated the efficacy of guanfacine in reducing target 
symptoms of ADHD in children and adolescents.5–7
As is the case with the more traditional psychostimu-
lants, methylphenidate and amphetamine, significant inter-
individual variability in response to guanfacine has been 
reported. For example, in a prospective trial of guanfacine 
in children with comorbid pervasive developmental disorder 
and ADHD, the improvement from baseline ADHD symptom 
scores ranged widely (ie, -1 to 41 points).8 Similarly, in a 
large retrospective chart review of children with pervasive 
developmental disorders receiving guanfacine, the rate of 
positive response ranged from 13% to 39%, depending 
on the patient population assessed.9 A trend indicating 
clear superiority of guanfacine over placebo, albeit with 
significant interindividual variability in endpoint ratings of 
ADHD symptoms, is a consistent finding in the published 
literature.6,10
Interindividual variation in drug response and disposi-
tion may be attributed to varied drug transporter activity, 
which is mediated by an array of single nucleotide poly-
morphisms (SNPs), as well as other endogenous and exog-
enous substances that may serve as transporter inhibitors or 
inducers.11,12 P-glycoprotein (P-gp) is the most thoroughly 
studied member of the adenosine triphosphate-binding cas-
sette transporter superfamily, and is expressed throughout 
the body in the intestinal epithelium, hepatocytes, renal 
tubular cells, adrenal gland, blood–brain barrier, blood–
testis barrier, and blood–placenta barrier.13 In humans, 
P-gp is encoded by the ABCB1/MDR1 gene.14,15 Because 
of its ubiquitous expression and broad specificity, changes 
in P-gp expression or efflux activity induced by drug treat-
ments, diet, environmental factors, or SNPs can greatly 
impact drug disposition, pharmacokinetics, and clinical 
response.16,17 Hence, identification of P-gp substrates is 
important for therapeutic optimization and the avoidance 
of drug–drug interactions.
Several published studies have investigated the potential 
interaction between guanfacine and P-gp. Mahar Doan et al 
conducted an in vitro study to determine whether guanfacine 
is a substrate of P-gp utilizing a   Transwell cell culture model 
with P-gp-expressing Madin Darby canine kidney cells. The 
ratio of the transport velocity of guanfacine in the direction 
of basolateral-to-apical to apical-to-basolateral was found to 
be 1.2,   indicating that guanfacine is not a P-gp substrate.18 
Similarly, based upon a computational method (topological 
  substructural molecular design approach), other investiga-
tors predicted that guanfacine would be unlikely to serve as 
a P-gp substrate.19
Although these data suggest that guanfacine is not a 
P-gp substrate, a recently published clinical study examined 
the potential influence of the known SNPs variant of P-gp, 
C3435T, on response to guanfacine treatment in children 
diagnosed with ADHD. The authors concluded that patients 
genotyped and found to carry the C3435T variant showed 
significantly less clinical improvement in ADHD symptoms 
relative to patients who were wild-type for the gene.20 The 
C3435T variant has previously been shown to influence 
both gene expression and substrate specificity of P-gp.17,21 
Thus, the association between therapeutic response and 
the C3435T SNPs suggests that P-gp plays a role in the 
transport of guanfacine. Therefore, the purpose of this study 
was to use a different cell line (human P-gp-overexpressing 
porcine kidney epithelial cell line LLC-PK1/MDR1) and a 
different in vitro model (intracellular uptake) relative to that 
previously published to determine if guanfacine is indeed a 
P-gp substrate.
Materials and methods
Materials
The porcine kidney epithelial cell line LLC-PK1 and 
human P-gp-overexpressing mutant LLC-PK1/MDR1 cells 
were kindly provided by Dr Kari Kivistö (Dr Margarete 
Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, 
Germany). Fetal bovine serum, trypsin, and Dulbecco’s 
Modified Eagle Medium containing 4500 mg/L glucose, 
4 mM l-glutamine, and sodium pyruvate were obtained from 
Hyclone Co (Logan, UT). Dulbecco’s   phosphate-buffered 
saline, penicillin, and streptomycin were purchased from 
Mediatech Inc (Herndon, VA). Guanfacine and rhodamine6G 
were obtained from Sigma Co (St Louis, MO). The Pierce 
bicinchoninic acid protein assay kit (Thermo Scientific, 
Rockford, IL) was used to determine protein   concentrations. 
All other agents were of high analytical grade and commer-
cially available.
cell cultures and intracellular  
uptake studies
LLC-PK1 and LLC-PK1/MDR1 cells were cultured at 37°C 
in Dulbecco’s Modified Eagle Medium supplemented with 
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in an atmosphere of 5% CO2 and 95% relative humidity. 
Cells (1 mL) were seeded into 24-well plates at a density 
of 1 × 105 cells/mL. Culture medium was replaced every 
two days until cells reached confluence. To investigate 
the potential influence of P-gp on guanfacine transport, 
intracellular accumulation of guanfacine was measured in 
LLC-PK1/MDR1 cells and P-gp-negative LLC-PK1 cells. 
Rhodamine6G, a well-known P-gp substrate, was included 
as a positive control. After cells reached confluence, the 
culture medium was replaced by transport buffer (serum-free 
Dulbecco’s Modified Eagle Medium) for a 30-minute prein-
cubation at 37°C. Transport buffer was then removed and the 
test compounds (5 µM rhodamine6G, 5 µM guanfacine, or 
50 µM guanfacine) were added, and an additional 60-minute 
incubation period commenced. Next, the solutions were dis-
carded, and the cells were washed three times with ice-cold 
Dulbecco’s phosphate-buffered saline and solubilized with 
1% Triton X-100. Intracellular accumulation of rhodamine6G 
was measured using a fluorescent microplate reader with 
a 530 nm excitation and a 580 nm emission wavelength, 
which is a well established method.22 Cellular retention of 
guanfacine was analyzed by the high-performance liquid 
chromatographic assay described below. The concentrations 
of rhodamine6G and guanfacine were calculated from their 
respective standard curves, and standardized with the cel-
lular protein content determined by a Pierce bicinchoninic 
acid protein kit.
high-performance liquid  
chromatographic analysis
A novel high-performance liquid chromatographic-ultraviolet 
detection method for guanfacine quantification was devel-
oped for this study. Briefly, 100 µL of acetonitrile containing 
the internal standard, p-nitrophenol 100 µM, was added to a 
100 µL sample and vortexed. Samples were centrifuged at 
13,200 rpm at 4°C for 30 minutes to remove proteins. The 
supernatant (50 µL) was injected into the high-performance 
liquid chromatography column for analysis. Separation 
was performed on a reverse-phase column (Luna 5µ C8, 
250 × 4.6 mm) at 40°C. The mobile phase consisted of 25% 
acetonitrile and 75% KH2PO4 (10 mM, pH 4), and the flow 
rate was 1.0 mL/min. Guanfacine was detected by ultraviolet 
absorption at 220 nm.
Data analysis
All data are presented as means ± standard deviation. 
  Intracellular concentrations of rhodamine6G and guanfacine 
in LLC-PK1/MDR1 cells are expressed as the percentages 
of that in LLC-PK1 cells. A two-tailed unpaired Student’s 
t-test was used for data analyses, with a P value of #0.5 
considered statistically significant.
Results
The P-gp substrate properties of guanfacine were assessed 
by measuring intracellular drug accumulations in LLC-
PK1 and LLC-PK1/MDR1 cells. The results shown in 
Figure 1 indicate that, at a guanfacine concentration of 
50 µM, the intracellular concentration of guanfacine was 
three-fold higher in LLC-PK1 cells than in   LLC-PK1/
MDR1 cells (35.9% ± 4.8% of LLC-PK1 cell uptake, 
P , 0.01). Similarly, at a guanfacine concentration of 5 µM, 
the intracellular concentration of guanfacine was two-fold 
higher in   LLC-PK1 cells than in LLC-PK1/MDR1 cells 
(49.0% ± 28.3%, P , 0.05). By comparison, the concentra-
tion of the positive P-gp control substrate, rhodamine6G, 
in LLC-PK1/MDR1 cells was only 5% of that in LLC-
PK1 cells. Overall, these results suggest that guanfacine is, 
at best, a weak substrate for P-gp.
Discussion
An estimated 100,000 patients die each year of adverse 
drug reactions in the US, thus making adverse drug reac-
tions one of the leading causes of death in hospitalized 
patients.23 Some of these deaths are caused by drug–drug 
interactions. Most drug interactions occur as an unexpected 
result of changes in pharmacokinetics due to drug coadmin-
istration. Combined pharmacotherapy in child, adolescent, 
and adult psychiatric patients has recently become a grow-
ing practice.24–26 Because ADHD therapeutic agents are 
the most commonly used psychotropic drugs in children 
0
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Figure  1  intracellular  concentrations  of  guanfacine  in  LLc-PK1  and  LLc-PK1/
MDr1  cells.  each  column  represents  the  mean  percentages  of  intracellular 
guanfacine concentrations relative to that in LLc-PK1 cells, with a bar representing 
the standard deviation of three independent measurements. 
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and adolescents and are often used in combination with 
other therapeutic agents on an acute or chronic basis, the 
potential for drug–drug interactions, at least in theory, is 
extremely high.27–29
Interaction of psychotropic drugs with P-gp has been well 
documented in recent years. For example, Uhr et al demon-
strated that a series of antidepressant medications, includ-
ing venlafaxine and paroxetine, are substrates for P-gp.30 
Additionally, Wang et al reported that the antipsychotic 
risperidone and its active metabolite, 9-  hydroxy-risperidone, 
are both P-gp substrates.31 Other psychotropic agents 
that have been documented as substrates of P-gp to some 
degree include (R)-  methadone, (S)-methadone, olanzapine, 
d-modafinil, l-modafinil, and d-methylphenidate.29,32,33 
Because P-gp is the most important efflux transporter at 
the blood–brain barrier, entry of these substrates into the 
central nervous system is greatly limited. Furthermore, a 
number of psychotropic drugs have been found to be P-gp 
inhibitors, which may affect disposition of coadministered 
P-gp substrates.29,34,35
Prominent variability of response has been reported in 
patients taking guanfacine to treat ADHD.6,8–10 In a recent 
study, variation in response to guanfacine correlated to a 
single nucleotide polymorphism of the MDR1 gene, the gene 
encoding for human P-gp.20 The present study was therefore 
performed to determine if guanfacine, like many other psy-
chotropic drugs, is a P-gp substrate.
The results of the intracellular accumulation study of 
guanfacine in P-gp-expressing cells suggest that guanfa-
cine is, at best, a weak P-gp substrate. Specifically, the 
accumulation of guanfacine in LLC-PK1/MDR1 cells 
was approximately 30%–50% of that in LLC-PK1 cells 
under our experimental conditions. In comparison, the 
intracellular concentration of the established P-gp substrate 
rhodamine6G in LLC-PK1/MDR1 cells was only 5% of 
that in control cells. Thus, it appears the role of P-gp in 
guanfacine transport is minor, and P-gp is unlikely to be 
one of the determinants of the interindividual variability in 
response to guanfacine therapy. Thus, the reported effect 
of the MDR1 SNP C3435T on the response to guanfacine 
treatment must be interpreted carefully and warrants further 
investigation.
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